889 related articles for article (PubMed ID: 26339043)
21. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses.
Descours B; Petitjean G; López-Zaragoza JL; Bruel T; Raffel R; Psomas C; Reynes J; Lacabaratz C; Levy Y; Schwartz O; Lelievre JD; Benkirane M
Nature; 2017 Mar; 543(7646):564-567. PubMed ID: 28297712
[TBL] [Abstract][Full Text] [Related]
22. The challenge of viral reservoirs in HIV-1 infection.
Blankson JN; Persaud D; Siliciano RF
Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
[TBL] [Abstract][Full Text] [Related]
23. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
[TBL] [Abstract][Full Text] [Related]
24. CD161
Li X; Liu Z; Li Q; Hu R; Zhao L; Yang Y; Zhao J; Huang Z; Gao H; Li L; Cai W; Deng K
mBio; 2019 Oct; 10(5):. PubMed ID: 31594817
[TBL] [Abstract][Full Text] [Related]
25. Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.
Seu L; Sabbaj S; Duverger A; Wagner F; Anderson JC; Davies E; Wolschendorf F; Willey CD; Saag MS; Goepfert P; Kutsch O
J Virol; 2015 Jul; 89(13):6656-72. PubMed ID: 25878110
[TBL] [Abstract][Full Text] [Related]
26. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
27. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
28. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART.
DaFonseca S; Niessl J; Pouvreau S; Wacleche VS; Gosselin A; Cleret-Buhot A; Bernard N; Tremblay C; Jenabian MA; Routy JP; Ancuta P
Retrovirology; 2015 Apr; 12():38. PubMed ID: 25924895
[TBL] [Abstract][Full Text] [Related]
29. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.
Siliciano RF
Top HIV Med; 2005; 13(3):96-100. PubMed ID: 16170226
[TBL] [Abstract][Full Text] [Related]
30. Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.
Laird GM; Rosenbloom DI; Lai J; Siliciano RF; Siliciano JD
Methods Mol Biol; 2016; 1354():239-53. PubMed ID: 26714716
[TBL] [Abstract][Full Text] [Related]
31. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
32. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
[TBL] [Abstract][Full Text] [Related]
33. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.
Chun TW; Nickle DC; Justement JS; Large D; Semerjian A; Curlin ME; O'Shea MA; Hallahan CW; Daucher M; Ward DJ; Moir S; Mullins JI; Kovacs C; Fauci AS
J Clin Invest; 2005 Nov; 115(11):3250-5. PubMed ID: 16276421
[TBL] [Abstract][Full Text] [Related]
34. Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART.
García M; Górgolas M; Cabello A; Estrada V; Ligos JM; Fernández-Guerrero M; Barros C; López-Bernaldo JC; De La Hera FJ; Montoya M; Benito JM; Rallón N
Sci Rep; 2017 Dec; 7(1):16799. PubMed ID: 29196729
[TBL] [Abstract][Full Text] [Related]
35. Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals.
Trejbalová K; Kovářová D; Blažková J; Machala L; Jilich D; Weber J; Kučerová D; Vencálek O; Hirsch I; Hejnar J
Clin Epigenetics; 2016; 8():19. PubMed ID: 26900410
[TBL] [Abstract][Full Text] [Related]
36. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
37. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
38. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
[TBL] [Abstract][Full Text] [Related]
39. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
40. Peering into the HIV reservoir.
García M; Buzón MJ; Benito JM; Rallón N
Rev Med Virol; 2018 Jul; 28(4):e1981. PubMed ID: 29744964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
